Eagle Global Advisors’s NovoCure NVCR Stock Holding History

Eagle Global Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,700	Closed	-$283K	–	228
2023 Q1	$283K	Hold	4,700	–	–	0.02%	193
2022 Q4	$345K	Hold	4,700	–	–	0.02%	183
2022 Q3	$357K	Hold	4,700	–	–	0.03%	177
2022 Q2	$327K	Sell	4,700 -1,000	-18%	-$75.3K	0.02%	185
2022 Q1	$472K	Sell	5,700 -1,400	-20%	-$103K	0.03%	177
2021 Q4	$533K	Hold	7,100	–	–	0.03%	173
2021 Q3	$825K	Buy	7,100 +2,400	+51%	+$363K	0.05%	152
2021 Q2	$1.04M	Hold	4,700	–	–	0.07%	143
2021 Q1	$621K	Hold	4,700	–	–	0.05%	172
2020 Q4	$813K	Hold	4,700	–	–	0.06%	142
2020 Q3	$523K	Buy	+4,700	New	+$376K	0.05%	146

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Eagle Global Advisors's NVCR Position: Q2 2023 in Review

Eagle Global Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 4,700 shares — an estimated $283K sold.

Eagle Global Advisors first reported a position in NVCR in Q3 2020 and held it in 11 quarters. The position peaked at $1.04M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

Eagle Global Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
Eagle Global Advisors sold 4,700 NovoCure shares in Q2 2023, an estimated $283K.
Eagle Global Advisors first reported a position in NovoCure in Q3 2020 and held it in 11 quarters.
Eagle Global Advisors's NovoCure position peaked at $1.04M in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Eagle Global Advisors's 13F filing for Q2 2023, filed 21 Jul 2023.